eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

The antitumour efficacy of hesperidin vs. cisplatin against non‐small lung cancer cells A549 and H460 via targeting the miR‐34a/PD-L1/NF-κB signalling pathway

Sherine M. Ibrahim
1
,
Maryam S. Sayed
1
,
Dina M. Abo-ElMatty
2
,
Noha M. Mesbah
2
,
Asmaa R. Abdel-Hamed
2

  1. Department of Biochemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza, Egypt
  2. Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt
Contemp Oncol (Pozn) 2024; 28 (2)
DOI: https://doi.org/10.5114/wo.2024.141648
Online publish date: 2024/07/19
Article file
- The antitumour.pdf  [0.86 MB]
Get citation
 
PlumX metrics:
 
1. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon 2020.
2. Assessing national capacity for the prevention and control of non-communicable diseases: report of the 2019 global survey. World Health Organization, Geneva 2020.
3. Park BJ, Yang HX, Woo KM, Sima CS. Minimally invasive (robotic-assisted thoracic surgery and video-assisted thoracic surgery) lobectomy for the treatment of locally advanced non-small cell lung cancer. J Thorac Dis 2016; 8: S406-S408.
4. De Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Global Health 2020; 8: e180-e190.
5. Xia R, Xu G, Huang Y, Sheng X, Xu X, Lu H. Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci 2018; 201: 111-120.
6. Kuntić V, Pejić N, Micić S. Direct spectrophotometric determination of hesperidin in pharmaceutical preparations. Acta Chimica Slovenica 2012; 59: 436-441.
7. Kamaraj S, Ramakrishnan G, Anandakumar P, Jagan S, Devaki T. Antioxidant and anticancer efficacy of hesperidin in benzo(A)pyrene induced lung carcinogenesis in mice. Invest New Drugs 2008; 27: 214-22.
8. Aggarwal M, Grady A, Desai D, et al. Successful implementation of healthful nutrition initiatives into hospitals. Am J Med 2020; 133: 19-25.
9. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99: 12293-12297.
10. Lin C, Chen X, Li M, et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer 2015; 16: e25-e35.
11. Elanany MM, Mostafa D, Hamdy NM. Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer. Life Sci 2023; 330: 121997.
12. Zhang Y, Wang L, Li Y, et al. A Comprehensive investigation of molecular features and prognosis of lung adenocarcinoma with micropapillary component. J Thor Oncol 2014; 9: 1772-1778.
13. Ikeda S, Okamoto T, Okano S, et al. PD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non–small cell lung cancer. J Thor Oncol 2016; 11: 62-71.
14. Ibrahim SM, Fayez AM, Maher A. Mesenchymal stromal cells suppress hepatic fibrosis via modulating expression of fibronectin and integrin and inhibiting DNA fragmentation in rats. Available from: DOI: https://doi.org/10.5114/aoms/134826
15. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
16. Nadia M. Hamdy. Relationship between pro-anti-inflammatory cytokines, T-cell activation and CA 125 in obese patients with heart failure. Med Sci Monit 2011; 17: CR174-179.
17. Hamdy NM, El-Wakeel L, Suwailem SM. Involvement of depressive catecholamines as thrombosis risk/inflammatory markers in non-smoker, non-obese congestive heart failure, linked to increased epidermal growth factor-receptor (EGF-R) production. Indian J Clin Biochem 2011; 26: 140-145.
18. Mak MP, William JrWN. Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol 2014; 50: 918-923.
19. Wang Z. Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges, and future research. Inte J Mol Sci 2016; 17: 95.
20. Mo’men YS, Hussein RM, Kandeil MA. Involvement of PI3K/Akt pathway in the protective effect of hesperidin against a chemically induced liver cancer in rats. J Biochem Mol Toxicol 2019; 33: e22305.
21. Mahmoud MM, Sanad EF, Hamdy NM. MicroRNAs’ role in the environment-related non-communicable diseases and link to multidrug resistance, regulation, or alteration. Environ Sci Pollut Res Int 2021; 28: 36984-37000.
22. Mahmoud MM, Sanad EF, Elshimy RAA, Hamdy NM. Competitive endogenous role of the LINC00511/miR-185-3p axis and miR-301a-3p from liquid biopsy as molecular markers for breast cancer diagnosis. Front Oncol 2021; 11: 749753.
23. Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 2016; 8: 1079-1085.
24. Takagawa Y, Gen Y, Muramatsu T, et al. MiR-1293, a candidate for miRNA-based cancer therapeutics, simultaneously targets BRD4 and the DNA repair pathway. Mol Ther 2020; 28: 1494-1505.
25. Zhang LZ, Yang JE, Luo YW, Liu FT, Yuan YF, Zhuang SM. A p53/lncIp53 negative feedback loop regulates tumor growth and chemoresistance. Adv Sci 2020; 7: 2001364.
26. Kwok GT, Zhao JT, Weiss J, et al. Translational applications of microRNAs in cancer, and therapeutic implications. Noncoding RNA Res 2017; 2: 143-150.
27. Shi J, Zhao Y, Wang Y, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 2014; 514: 187-192.
28. Pasparakis M. Role of NF-B in epithelial biology. Immunol Rev 2012; 246: 346-358.
29. Cooks T, Pateras IS, Tarcic O, et al. Mutant p53 prolongs NF-B activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 2013; 23: 634-646.
30. Gilmore TD, Garbati MR. Inhibition of NF-B signaling as a strategy in disease therapy. In: Karin E (ed.). NF-kB in health and disease. Springer, Berlin 2010, 245-263.
31. Allam RM, Al-Abd AM, Khedr A, Sharaf OA. Fingolimod interrupts the cross-talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett 2018; 291: 77-85.
32. Fekry MI, Ezzat SM, Salama MM, Alshehri OY, Al-Abd AM. Bioactive glycoalkaloids isolated from Solanum melongena fruit peels with potential anticancer properties against hepatocellular carcinoma cells. Sci Rep 2019; 9: 1746.
33. Martinotti S, Ranzato E. Scratch wound healing assay. In: Turksen K.Epidermal cells. Methods in molecular biology, Springer, Berlin 2019, 2109.
34. Andriani F, Perego P, Carenini N, Sozzi G, Roz L. Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene tran neoplasia. Neoplasia 2006; 8: 9-17.
35. Perego P, Beretta G, Gatti L. Identification of determinants of sensitivity to antitumor drugs. In: Conn PM (ed.). Handbook of proteomic methods. Humana Press Inc., Totowa, NJ 2003, 319-331.
36. Choi YM, Kim HK, Shim W, et al. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One 2015; 10: e0135083.
37. Xia R, Sheng X, Xu X, Yu C. Lu H. Hesperidin induces apoptosis and G0/G1 arrest in human non-small cell lung cancer A549 cells. Int J Mol Med 2018; 41: 464-472.
38. Hafez MM, Abdel-Hafez LM, Jamil L, Ibrahim SM. Association between cluster of differentiation 24 (CD24) polymorphism, talin-1 gene expression and hepatocellular carcinoma prevalence in the Egyptian population. Available from: DOI: https://doi.org/10.5114/aoms/140451.
39. Longchar A, Prasad SB. Biochemical changes associated with ascorbic acid-cisplatin combination therapeutic efficacy and protective effect on cisplatin-induced toxicity in tumor-bearing mice. Toxicol Rep 2015; 7: 489-503.
40. Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Med Princ Pract 2016; 25: 41-59.
41. Garg A, Garg S, Zaneveld LJD, Singla AK. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 2001; 15: 655-669.
42. Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res 2015; 29: 323-331.
43. Tanaka T, Makita H, Ohnishi M, et al. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. Cancer Res 1997; 57: 246-252.
44. Birsu Cincin Z, Unlu M, Kiran B, Sinem Bireller E, Baran Y, Cakmakoglu B. Anti-proliferative, apoptotic, and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cell Oncol 2015; 38: 195-204.
45. Xia R, Xu G, Huang Y, Sheng X, Xu X, Lu H. Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci 2018; 201: 111-120.
46. Reedijk J, Lohman, PHM. Cisplatin: synthesis, antitumor activity and mechanism of action. Pharm Weekbl Sci 1985; 7: 173-180.
47. Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin Oncol 1999; 11: 116-122.
48. Concato VM, Tomiotto-Pellissiera F, Silva TF, et al. 3,3’,5,5’-tetramethoxybiphenyl-4,4’diol induces cell cycle arrest in G2/M phase and apoptosis in human non -small cell lung cancer A549 cells. Chem Biol Interact 2020; 326: 109133.
49. Kabała-Dzik A, Rzepecka-Stojko A, Kubina R, et al. Flavonoids, bioactive components of propolis, exhibit cytotoxic activity and induce cell cycle arrest and apoptosis in human breast cancer cells MDA-MB-231 and MCF-7 – a comparative study. Cell Mol Biol 2018; 64: 1-10.
50. Bodduluru LN, Kasala ER, Barua CC, Karnam KC, Dahiya V, Ellutla M. Antiproliferative and antioxidant potential of hesperetin against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Chem Biol Interact 2015; 242: 345-352.
51. Aggarwal V, Tuli H, Thakral F, Singhal P, Aggarwal D, Srivastava S. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Exp Biol Med (Maywood) 2020; 245: 486-497.
52. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3: 1355-1363.
53. Gong B, Kiyotani K, Sakata S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med 2019; 216: 982-1000.
54. Wang Q, Lin W, Tang X, et al. The roles of microRNAs in regulating the expression of PD-1/PD-L1 immune checkpoint. Int J Mol Sci 2017; 18: 2540.
55. Zhang Y, Yang P, Wang XF. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol 2014; 24: 153-160.
56. Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 checkpoint. Immunity 2018; 48: 434-452.
57. Cortez MA, Ivan C, Valdecanas D, et al. PDL1 regulation by p53 via miR-34. J Natl Cancer Inst 2016; 108: djv303.
58. Donia TIK, Gerges MN, Mohamed TM. Amelioration effect of Egyptian sweet orange hesperidin on Ehrlich ascites carcinoma (EAC) bearing mice. Chem Biol Interact 2018; 285: 76-84.
59. Chang CJ, Chao CH, Xia W, et al. P53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
60. Xu S, Tao Z, Hai B, et al. MiR-424 (322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun 2016; 7: 11406.
61. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010; 2: 2490-2518.
62. Aldossary SA. Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Biomed Pharmacol J 2019; 12: 7-15.
63. Sahu BD, Kuncha M, Sindhura GJ, Sistla R. Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation, and DNA damage. Phytomedicine 2013; 20: 453-460.
64. Birsu Cincin Z, Unlu M, Kiran B, Sinem Bireller E, Baran Y, Cakmakoglu B. Anti-proliferative, apoptotic, and signal transduction effects of hesperidin in non-small cell lung cancer cells. Cell Oncol 2015; 38: 195-204.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.